Abstracts tagged "Malignancy"

Abstract Number: 802 • 2013 ACR/ARHP Annual Meeting
Tofacitinib, An Oral Janus Kinase Inhibitor: Analysis Of Malignancies Across The Rheumatoid Arthritis Clinical Program
X. Mariette¹, J. R. Curtis², E. B. Lee³, B. Benda⁴, I. Kaplan⁵, K. Soma⁵, R. Chew⁵, J. Geier⁶, L. Wang⁷ and R. Riese⁵, ¹Paris-Sud University, Paris, France, ²Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ³Seoul National University, Seoul, South Korea, ⁴Pfizer Inc, Collegeville, PA, ⁵Pfizer Inc, Groton, CT, ⁶Pfizer Inc, New York, NY, ⁷Pfizer Worldwide R&D, Cambridge, MA
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). This analysis extended the evaluation of malignancies that occurred…
Abstract Number: 782 • 2013 ACR/ARHP Annual Meeting
Rates Of Malignancies In Patients From 5 Rheumatoid Arthritis Registries Across The World
Johan Askling¹, Niklas Berglind², Stefan Franzén², Thomas Frisell³, Christopher Garwood⁴, Jeffrey D. Greenberg⁵, Meilien Ho⁶, Marie Holmqvist¹, Laura Horne⁷, Kathy Lampl⁸, Kaleb Michaud⁹, Fredrik Nyberg¹⁰, Dimitrios A. Pappas¹¹, George Reed¹², Eiichi Tanaka¹³, Trung Tran¹⁴, Suzanne Verstappen⁴, Hisashi Yamanaka¹⁵ and Deborah Symmons⁴, ¹Karolinska Institutet, Stockholm, Sweden, ²AstraZeneca R&D Mölndal, Mölndal, Sweden, ³Clinical Epidemiology Unit, Dept of Medicine, Karolinska Institutet, Stockholm, Sweden, ⁴Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, ⁵Division of Rheumatology, Department of Medicine, NYU Hospital for Joint Diseases, New York, NY, ⁶AstraZeneca R&D Alderley Park, Macclesfield, United Kingdom, ⁷AstraZeneca, Wilmington, DE, ⁸AstraZeneca R&D Wilmington, Wilmington, DE, ⁹University of Nebraska Medical Center and National Data Bank, Omaha, NE, ¹⁰AstraZeneca R&D, Mölndal, Sweden, ¹¹Columbia University, New York, NY, ¹²University of Massachusetts Medical School, Worcester, MA, ¹³Tokyo Women's Medical University, Tokyo, Japan, ¹⁴MedImmune LLC, Gaithersburg, MD, ¹⁵Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan
Background/Purpose: The overall incidence of cancer in patients with rheumatoid arthritis (RA) is modestly elevated compared with the general population. The extent to which cancer…
Abstract Number: 1593 • 2012 ACR/ARHP Annual Meeting
The Risk of Lymphoma in Patients Receiving Anti-Tumor Necrosis Factor Therapy for Rheumatoid Arthritis: Results From the British Society for Rheumatology Biologics Register – Rheumatoid Arthritis
Louise K. Mercer¹, Mark Lunt², Audrey S. Low³, James B. Galloway², Kath Watson⁴, William G. Dixon⁵, BSRBR Control Centre Consortium², Deborah P. Symmons³, Kimme L. Hyrich⁶ and On behalf of the BSRBR⁷, ¹Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester, United Kingdom, ²Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, ³Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom, ⁴Arthritis Research UK Epidemiology Unit, Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, ⁵The University of Manchester, Manchester, United Kingdom, ⁶Manchester Academic Health Science Centre, Arthritis Research UK Epidemiology Unit, Manchester, United Kingdom, ⁷British Society for Rheumatology, London, United Kingdom
Background/Purpose: The risk of lymphoma is increased in people with RA compared to the general population and is greatest in severe RA. Anti-TNF therapy is…
Abstract Number: 707 • 2012 ACR/ARHP Annual Meeting
Risk of Cancer in Systemic Sclerosis: Meta-Analysis of Population-Based Cohort Studies
Akira Onishi¹, Daisuke Sugiyama², Akio Morinobu³ and Shunichi Kumagai⁴, ¹Rheumaology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ²Department of Preventive Medicine and Public Health, School of Medicine, Keio University, Tokyo, Japan, ³Department of Clinical Pathology and Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ⁴Center of Rheumatic Diseases, Shinko Hospital, Kobe, Japan
Background/Purpose: The risk of cancer compared with general population has been elevated in several connective tissue diseases. However, the standardized incidence ratios (SIRs) for overall…
Abstract Number: 224 • 2012 ACR/ARHP Annual Meeting
Standardized Incidence Ratios and Predictors of Malignancies in 215 Southern Chinese Patients with Inflammatory Myopathies
Chi Chiu Mok¹, Chi Hung To¹, ML Yip² and King Yee Ying³, ¹Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong, ²Division of Rheumatology, Department of Medicine, Kwong Wah Hospital, Kowloon, Hong Kong, ³Department of Medicine, Princess Margaret Hospital, Hong Kong, Hong Kong
Background/Purpose: To examine the standardized incidence ratios (SIRs) and predictive factors for malignancy in a cohort of southern Chinese patients with inflammatory myopathies (IM). Methods:…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].